Embecta Corp. logo

Embecta Corp. (EMBC)

Market Closed
12 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
11. 80
-0.14
-1.21%
$
735.16M Market Cap
10.78 P/E Ratio
0.6% Div Yield
903,204 Volume
2.1 Eps
$ 11.95
Previous Close
Day Range
11.66 12.1
Year Range
9.2 21.23
Want to track EMBC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 8 days

Summary

EMBC closed Friday lower at $11.8, a decrease of 1.21% from Thursday's close, completing a monthly decrease of -6.09% or $0.77. Over the past 12 months, EMBC stock lost -43.19%.
EMBC pays dividends to its shareholders, with the most recent payment made on Sep 15, 2025. The next announced payment will be in In 3 days on Dec 18, 2025 for a total of $0.15.
The last earnings report, released on Nov 25, 2025, exceeded the consensus estimates by 0.04%. On average, the company has fell short of earnings expectations by -0.21%, based on the last three reports. The next scheduled earnings report is due on Dec 23, 2025.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

EMBC Chart

Similar

Bel Fuse Inc.
$ 173.22
-1.22%
Innospec Inc.
$ 78.24
-0.48%
Strategic Education Inc.
$ 80.82
-0.17%
Perdoceo Education Corporation
$ 28.88
+0.59%
Bel Fuse Inc.
$ 151.52
-2.5%
Embecta Corp. (EMBC) Q4 2025 Earnings Call Transcript

Embecta Corp. (EMBC) Q4 2025 Earnings Call Transcript

Embecta Corp. ( EMBC ) Q4 2025 Earnings Call November 25, 2025 8:00 AM EST Company Participants Pravesh Khandelwal - VP & Head of Investor Relations Devdatt Kurdikar - President, CEO & Director Jake Elguicze - Senior VP & CFO Conference Call Participants Marie Thibault - BTIG, LLC, Research Division Michael Polark - Wolfe Research, LLC Anthony Petrone - Mizuho Securities USA LLC, Research Division Gracia Mahoney - BofA Securities, Research Division Presentation Operator Welcome, ladies and gentlemen, to Embecta Corp.'s Fiscal Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and a replay will be available on the company's website following the call.

Seekingalpha | 2 weeks ago
Best Value Stocks to Buy for September 9th

Best Value Stocks to Buy for September 9th

JXN, EMBC and KT made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 9, 2025.

Zacks | 3 months ago
Embecta Corp. (EMBC) Q3 2025 Earnings Call Transcript

Embecta Corp. (EMBC) Q3 2025 Earnings Call Transcript

Embecta Corp. (NASDAQ:EMBC ) Q3 2025 Earnings Conference Call August 8, 2025 8:00 AM ET Company Participants Devdatt Kurdikar - President, CEO & Director Jacob P. Elguicze - Senior VP & CFO Pravesh Khandelwal - VP & Head of Investor Relations Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Gracia Leydon Mahoney - BofA Securities, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Michael K.

Seekingalpha | 4 months ago

Embecta Corp. (EMBC) FAQ

What is the stock price today?

The current price is $11.80.

On which exchange is it traded?

Embecta Corp. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is EMBC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.6%.

What is its market cap?

As of today, the market cap is 735.16M.

What is the earnings per share?

The EPS is 0.46.

When is the next earnings date?

The next earnings report will release on Dec 23, 2025.

Has Embecta Corp. ever had a stock split?

No, there has never been a stock split.

Embecta Corp. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Devdatt Kurdikar CEO
NASDAQ (NGS) Exchange
29082K105 CUSIP
US Country
2,000 Employees
5 Dec 2025 Last Dividend
- Last Split
1 Apr 2022 IPO Date

Overview

Embecta Corp. stands as a pioneering medical device company with its focus sharply attuned to enhancing the health and wellbeing of individuals battling diabetes. With its roots planted as far back as 1924, Embecta has burgeoned into a flagship enterprise, dedicated to delivering innovative solutions for diabetes management. Operating from its headquarters in Parsippany, New Jersey, the company has marked its presence both in the United States and on an international spectrum, predominantly through wholesalers and distributors. The essence of Embecta's mission revolves around its commitment to supporting people with diabetes through its extensive range of products and digital applications designed for efficacious diabetes management.

Products and Services

  • Pen Needles
  • Pen needles from Embecta are tailored for ease of use and comfort, meeting the diverse needs of individuals requiring insulin or other injectable diabetes medications. These needles are designed to facilitate a less painful insertion process, enhancing the overall experience of daily diabetes management.

  • Syringes
  • Embecta presents a range of syringes geared towards ensuring accuracy, safety, and comfort during insulin delivery. These syringes are constructed with patient safety in mind, incorporating features that aim to minimize injection-related anxiety and complications.

  • Safety Injection Devices
  • The company's Safety Injection Devices are developed with cutting-edge technology to mitigate the risks associated with needlestick injuries, a concern for both healthcare providers and patients. These devices embody the essence of Embecta's commitment to safety in diabetes care.

  • Digital Applications
  • Recognizing the growing need for digital health solutions, Embecta has ventured into providing digital applications designed to assist individuals in managing their diabetes more effectively. These applications offer tools for monitoring blood sugar levels, medication tracking, and personalized insights into one’s diabetes management plan, ultimately aiming to empower users with control over their health.

Contact Information

Address: 300 Kimball Drive
Phone: 201 847 6880